>

Ziv Kop - KAMADA Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>KMD</div>
KMDA -- Israel Stock  

ILA 1,963  35.00  1.75%

  Director
Mr. Ziv Kop is Independent Director at Kamada Ltd. He has served on our board of directors since May 2005. Since March 2014 Mr. Kop is the Chief Operating Officer of Outbrain Inc., where he has served as a board member since 2006. From October 2003 to August 2013, Mr. Kop served as Managing Partner at GlenRock Israel Ltd., a private equity investment firm, where he managed a portfolio of growth companies in the fields of advanced technologies and healthcare, including Evogene Ltd., , Mobileye N.V., Quigo Technologies Inc., Outbrain Inc., Rainbow Medical Ltd. From 2003 to 2012, Mr. Kop served as Chief Executive Officer of Roei Medical Technologies Ltd. Mr. Kop currently serves on the board of directors of Evogene Ltd., a plant genomics company listed on the TASE and New York Stock Exchange, and he previously served on the board of Mobilemax Ltd., a company listed on the TASE, from 2007 to 2013. Mr. Kop has also served on the boards of the following private companies Outbrain Inc. since 2006, TOOT Trading Technologies Ltd. since 2010, Rainbow Medical from 2007 to 2013, Lifebond Ltd. from 2007 to 2013, Gmul Investments Ltd. from 2008 to 2012 and Gmul Nadlan Ltd. from 2008 to 2012. Prior to joining GlenRock, Mr. Kop served as Chief Executive Officer of POC Management Consulting, Ltd., a leading Israeli consultancy in the field of strategic planning, from 2002 to 2003. Mr. Kop holds a L.L.B. degree and an MA degree in Law and Business Administration, both from Tel Aviv University, and he is a graduate of INSEAD Young Managers Program.
Age: 43  Director Since 2005      
(972) 8 9406472  www.kamada.com
Kop holds an LLB and a Bachelor in Management from Tel Aviv University and has graduated INSEAD YMP.

Management Efficiency

The company has return on total asset (ROA) of 0.17 % which means that it generated profit of $0.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 0.21 % meaning that it generated $0.21 on every $100 dollars invested by stockholders.
The company has accumulated 5.75 M in total debt with debt to equity ratio (D/E) of 4.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. KAMADA has Current Ratio of 6.02 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Shmuel LeshemARAD LTD
2019
Ronny BarnirARAD LTD
2016
Reuven LevinMEDTECHNICA
N/A
Tova PintoARAD LTD
2011
Asaf BartfeldDELEK AUTOMOTIVE S
1992
Irit TobiasDELEK AUTOMOTIVE S
2018
Daniel VakninARAD LTD
2017
Oded TiraARAD LTD
2007
Uri MeitalARAD LTD
2019
Gabriel LastDELEK AUTOMOTIVE S
2010
Malka DorDELEK AUTOMOTIVE S
2011
Rony BrenerARAD LTD
2010
Tal YaronEldarMEDTECHNICA
2012
Yaakov DromyARAD LTD
2010
Morris BenistyMEDTECHNICA
2019
Serhin VekslerARAD LTD
2011
Amos BendrorARAD LTD
2016
Claude ShaulMEDTECHNICA
2012
Amos MalkaDELEK AUTOMOTIVE S
2010
Ephraim AbramsonARAD LTD
2017
Saul YemalMEDTECHNICA
2012

Company Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 429 people.KAMADA (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 429 people.

KAMADA Leadership Team

Pnina Strauss, Vice President - Inhalation programs & IPView
Itzhak Krinsky, DirectorView
Barak Bashari, Vice President - OperationsView
Eran Schenker, Vice President - Medical DirectorView
Tuvia Shoham, Independent DirectorView
Michal Stein, Vice President and Medical Director for ImmunologyView
Shani Dotan, Vice President of Human ResourcesView
Liliana Bar, VP of RandDView
Yael Brenner, Vice President - QualityView
Abraham Havron, Independent DirectorView
Asaf Frumerman, DirectorView
Ruth Wolfson, Senior Vice President - Scientific AffairsView
Shmuel Rubinstein, DirectorView
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary DiseasesView
Michael Berelowitz, DirectorView
David Tsur, Co-Founder and Deputy Executive ChairmanView
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&DView
Leon Recanati, Chairman of the BoardView
Gil Efron, CFO, Principal Accounting Officer and Deputy CEOView
Jonathan Hahn, DirectorView
Eran Schenkar, Vice President - Medical DirectorView
Gwen Melincoff, DirectorView
Chaime Orlev, Chief Financial OfficerView
Michal Ayalon, Vice President - Research & DevelopmentView
Amir London, Chief Executive OfficerView
Estery GilozRan, Independent DirectorView
Reuven Behar, DirectorView
Eitan Kyiet, Vice President - Business DevelopmentView
Ziv Kop, DirectorView

Stock Performance Indicators

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page